Search the Newsreel

Vestis (NYSE: VSTS) boosts 2026 free cash flow outlook after Q3 profit jump

Vestis Corporation (NYSE: VSTS) reported strong fiscal third-quarter 2026 results, leading to an increased free cash flow outlook for fiscal year 2026. The company's net income improved to $11.0 million, and Adjusted EBITDA rose to $80.9 million, driven by strategic transformation initiatives, improved pricing, …

[10-Q] Vestis Corp Quarterly Earnings Report

Vestis Corp (VSTS) has released its Quarterly Earnings Report (Form 10-Q) for the period ended July 3, 2026, showing a significant improvement in net income compared to the previous year. The company reported a net income of $11.0 million for the quarter, up from …

Vestis: Fiscal Q3 Earnings Snapshot

This article provides a fiscal Q3 earnings snapshot for Vestis. No further details are available as the article content was empty except for privacy protection information.

Vestis Corp 3Q FY2026: Revenue $661.7M, EPS $0.08— 10-Q Summary

Vestis Corp reported its third-quarter FY2026 results, showing revenue of $661.7 million and diluted EPS of $0.08. Despite a slight revenue decline, the company improved profitability to $11 million net income, attributed to cost actions and a transformation plan aimed at standardizing operations and …

Renaissance Technologies LLC Has $2.17 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Renaissance Technologies LLC significantly reduced its stake in Prestige Consumer Healthcare Inc. (PBH) by 62% in the first quarter, selling 59,900 shares but retaining 36,702 shares valued at approximately $2.17 million. Despite this, institutional investors collectively own 99.95% of PBH. Prestige Consumer Healthcare reported …

Quantinno Capital Management LP Acquires 19,281 Shares of Prestige Consumer Healthcare Inc. $PBH

Quantinno Capital Management LP significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by acquiring 19,281 shares, bringing its total holdings to 36,990 shares valued at $2.19 million. Institutional investors collectively own 99.95% of PBH. The company also surpassed quarterly earnings expectations, reporting …

CELESTICA INC. : SCOTIABANK RESUMES COVERAGE WITH SECTOR OUTPERFORM RATING; TARGET PRICE $500

Scotiabank has resumed coverage on Celestica Inc. (CLS.N) with a "Sector Outperform" rating and set a target price of $500. This news was reported by Reuters on August 11, 2026. The article reiterates this key financial analyst update without further elaboration.

Aquestive Therapeutics (AQST) Earnings Date and Reports 2026

Prestige Consumer Healthcare (PBH) Is Up 5.6% After Raising Fiscal 2027 Outlook on Acquisitions

Prestige Consumer Healthcare (PBH) saw its stock rise by 5.6% after reporting its fiscal 2027 first-quarter results and subsequently raising its full-year outlook. The company's updated revenue guidance of US$1.29 billion–US$1.32 billion and GAAP diluted EPS guidance of US$4.18–US$4.28 are primarily driven by recent …

EXECUTIVE MOVES | DXL APPOINTS CURRENT CHAIRMAN LIONEL CONACHER AS INTERIM CEO

Destination XL Group, Inc. (DXL) has appointed its current Chairman, Lionel Conacher, as Interim Chief Executive Officer. Conacher will continue as Chairman while the company conducts a search for a permanent CEO. He outlined a strategy focusing on profitability, cost reduction, assortment evolution, and …

Vestis faces earnings test after Q2 miss, transformation in focus

Vestis Corp. is scheduled to release its fiscal third-quarter earnings, which will be a crucial test of its turnaround strategy following a significant Q2 miss. Analysts anticipate 50 cents EPS and $834.2 million in revenue, a notable improvement from the previous quarter, but investor …

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ sublingual film, an epinephrine product for severe allergic reactions. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in the third quarter of …

Prestige Consumer Executives Set for Aug. 12 Fireside Chat

Prestige Consumer Healthcare Inc. (NYSE: PBH) announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at …

Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference

Prestige Consumer Healthcare Inc. announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Wednesday, August …

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics (AQST) announced positive results from human factors and pharmacokinetic validation studies for its Anaphylm sublingual film, a severe allergy treatment. These studies address prior FDA feedback, demonstrating significant improvements in product usability and effective drug delivery even with slight misplacement. The company …

First Majestic Silver Target of Unusually High Options Trading (NYSE:AG)

Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Up - Should You Buy?

DXL board chair steps in for CEO as challenges mount

Harvey Kanter, CEO of Destination XL Group (DXL), is retiring, and board chair Lionel Conacher will assume the interim CEO role. DXL faces several challenges, including the impact of weight-loss drugs on sales, a pending merger with FullBeauty Brands that the board is reconsidering, …

First Majestic Silver Aktie: 90-Millionen-Verkauf von San Martin

CELESTICA INC. : TD COWEN RESUMES COVERAGE WITH BUY RATING; TARGET PRICE $430

TD Cowen has resumed coverage of Celestica Inc. (CLS.N) with a Buy rating. The firm has set a target price of $430 for the company's stock. This announcement was made by Reuters on August 10, 2026.

Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside

Aquestive Therapeutics Inc (AQST) is preparing to release its Q2 2026 earnings on August 11, 2026, with revenue expected at $11.42 million and earnings at $-0.12 per share. While analysts predict a significant upside of 125.61% based on average price targets, GuruFocus's GF Value …

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film

Aquestive Therapeutics has announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in Q3 2026, addressing previous issues with packaging and administration. …

Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials

Aquestive Therapeutics has released supplemental materials on human factors and clinical results for its Anaphylm (dibutepinephrine) sublingual film program. A resubmission human factors study showed fewer use issues compared to the original NDA study, with a median open time reduced to 3 seconds. A …

Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026

Aquestive announced positive human factors and pharmacokinetic (PK) results for Anaphylm, indicating significant improvements in usability and comparable drug delivery. These results support the planned New Drug Application (NDA) resubmission in Q3 2026 for the epinephrine treatment. The study showed reduced errors in self-administration …

Celestial Asia Subsidiary Signs HK$10.6 Million Lease to Expand Pricerite Retail Network

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its officers. The lawsuit, filed on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, alleges that the company made false …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) who bought securities prior to June 16, 2025, and still hold them. The investigation aims to determine if Aquestive officers engaged in corporate wrongdoing. The firm …

3 Reasons to Avoid HAIN and 1 Stock to Buy Instead

Hain Celestial has seen a significant stock drop, and analysts are cautious due to declining organic sales (6.4% year-on-year), a 32.1% annual EPS decline over three years, and high debt levels ($549.5 million vs. $44.31 million cash) resulting in a 6x net-debt-to-EBITDA ratio. The …

Vestis (VSTS) Reports Earnings Tomorrow: What To Expect

Vestis Corporation (VSTS) is set to report its Q2 earnings, with analysts expecting flat year-on-year revenue. The company beat revenue expectations last quarter but had in-line EPS. While the industrial & environmental services sector has shown positive sentiment, Vestis's stock is down over the …

Celestica Inc (CLS) Stock News Today

This article provides recent news updates for Celestica Inc (CLS) stock, highlighting significant price movements. It lists instances where the stock moved down by 12.58% on August 6th, and moved up by 8.04% on May 29th, 6.70% on April 14th, and 7.05% on April …

Prestige Consumer Healthcare (PBH) Following Its 2027 Outlook Raise And The Undervalued View

Prestige Consumer Healthcare (PBH) has raised its fiscal 2027 revenue and earnings outlook, projecting revenue between $1.29b and $1.32b and GAAP diluted EPS between $4.18 and $4.28, driven by the integration of two recent acquisitions. Despite a mixed share price performance over the past …

Destination XL Group (NasdaqCM:DXLG) Stock Price

Destination XL Group (DXLG) stock is currently trading at US$0.64, significantly below its fair value estimates of US$1.00 to US$1.50, indicating it is undervalued. The company recently announced the appointment of Lionel Conacher as Interim CEO and a transfer of its stock listing from …

Read This Before Considering Prestige Estates Projects Limited (NSE:PRESTIGE) For Its Upcoming ₹2.00 Dividend

Westinghouse Air Brake Technologies (WAB) Stock Looks Near Fair Value On Cash Flow But Rich On Earnings

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Westinghouse Air Brake Technologies stock has delivered very strong long term returns over the past five years, yet the valuation checks suggest it no …

Vestis Corporation (VSTS) Stock Forecasts

Argus lowered its target price for Vestis Corporation (VSTS) to $15.00 as of August 5, 2026. Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. The report offers a summary of the company's services and suggests …

Prestige Consumer Healthcare (PBH) Stock Faces Margin Questions Despite Record Cash Flow